Charles River Labs Intl Stock
Charles River Labs Intl Stock
There is an upward development for Charles River Labs Intl compared to yesterday, with an increase of €1.70 (1.120%).
With 23 Buy predictions and not a single Sell prediction Charles River Labs Intl is an absolute favorite of our community.
As a result the target price of 165 € shows a slightly positive potential of 7.63% compared to the current price of 153.3 € for Charles River Labs Intl.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 1.120% | 0.597% | -0.623% | 72.351% | -12.192% | -18.517% | -41.240% |
| Ligand Pharmaceuticals | 0.550% | 1.676% | -0.546% | 97.826% | 9.639% | 177.863% | 49.425% |
| United Therapeutics | 0.760% | 0.327% | 4.602% | 98.224% | 14.908% | 138.813% | 194.012% |
| Ionis Pharmaceuticals Inc. | 1.150% | -1.696% | 2.246% | 167.478% | -6.210% | 86.866% | 85.398% |
Comments
Charles River Laboratories International (CRL) had its "outperform" rating reaffirmed by Evercore Inc.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat